Human-engineered Treg-like cells suppress FOXP3-deficient T cells but preserve adaptive immune responses in vivo.

ABSTRACT:

Objectives

Genetic or acquired defects in FOXP3⁺ regulatory T cells (Tregs) play a key role in many immune-mediated diseases including immune dysregulation polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Previously, we demonstrated CD4⁺ T cells from healthy donors and IPEX patients can be converted into functional Treg-like cells by lentiviral transfer of FOXP3 (CD4^LVFOXP3). These CD4^LVFOXP3 cells have potent regulatory function, suggesting their potential as an innovative therapeutic. Here, we present molecular and preclinical in vivo data supporting CD4^LVFOXP3 cell clinical progression.

Methods

The molecular characterisation of CD4^LVFOXP3 cells included flow cytometry, qPCR, RNA-seq

SUBMITTER: Sato Y 

PROVIDER: S-EPMC7688376 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature